Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 20/20 | 0.62 |
| ▸ | FLT4 | P35916 | 20/20 | 0.62 |
| ▸ | KDR | P35968 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tasisulam SCHEMBL29376914 | 1.00 | FLT1 (0.62) | FLT1FLT4KDR | |
| Tasisulam SCHEMBL1662355 | 0.99 | FLT1 (0.61) | FLT1FLT4KDR | |
| SCHEMBL5514080 | 0.90 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL5966429 | 0.90 | FLT1 (0.65) | FLT1FLT4KDR | |
| SCHEMBL5966441 | 0.87 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL5966464 | 0.87 | FLT1 (0.53) | FLT1FLT4KDR | |
| SCHEMBL5966461 | 0.87 | FLT1 (0.57) | FLT1FLT4KDR | |
| SCHEMBL5966505 | 0.86 | FLT1 (0.63) | FLT1FLT4KDR | |
| SCHEMBL5966433 | 0.84 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL21741575 | 0.84 | FLT1 (0.60) | FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108558822-B | Synthesis method of N- ((5-bromothiophene-2-yl) sulfonyl) -2, 4-dichlorobenzamide | 盐城锦明药业有限公司 | 2020-12-18 | — | — | CN | claimed |
| US-20100291592-A1 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-18 | — | — | US | claimed |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| EP-2015070-A1 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-14 | — | — | EP | claimed |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | US | claimed |
| EP-1862179-A1 | NOVEL USE OF SULFONAMIDE COMPOUND IN COMBINATION WITH ANGIOGENESIS INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2007-12-05 | — | — | EP | claimed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | claimed |
| EP-1859797-A1 | NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | claimed |
| US-7250430-B2 | Thiophene-and thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA S | 2006-10-05 | — | — | US | claimed |
| EP-1442030-B1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | LILLY CO ELI (US) | 2006-08-30 | — | — | EP | claimed |
| US-7084170-B2 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2006-08-01 | — | — | US | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA SUE (US) | 2004-10-07 | — | — | US | claimed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | claimed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | claimed |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | FLT1 76/4885FLT4 51/4885KDR 31/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | FLT1 3/4885FLT4 1/4885KDR 2/4885 |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | TPMT, TST, MGMT | FLT1 2922/4885FLT4 2768/4885KDR 4359/4885 |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | ACTR2, RPS6KB2, EPB41L2 | FLT1 4087/4885FLT4 3200/4885KDR 3001/4885 |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | TOP1, TOP2A, TOP2B | FLT1 220/4885FLT4 181/4885KDR 231/4885 |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ALDH1A2, MGMT, NR2E3 | FLT1 206/4885FLT4 444/4885KDR 557/4885 |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | KDR, FLT4, FLT1 | FLT1 3/4885FLT4 2/4885KDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.